SCHEMBL3523104

SCHEMBL3523104

CN1C(=O)NC(c2ccccc2)c2cc3c(cc21)OCO3

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.52
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
HTT P42858 2/20 0.43
ALDH1A1 P00352 7/20 0.41
KDM4E B2RXH2 6/20 0.41
GAA P10253 5/20 0.41
HSD17B10 Q99714 4/20 0.41
LMNA P02545 3/20 0.41
HPGD P15428 3/20 0.41
TSHR P16473 2/20 0.41
GLA P06280 1/20 0.41
CASP1 P29466 1/20 0.41
CASP7 P55210 1/20 0.41
USP2 O75604 1/20 0.41
POLB P06746 2/20 0.39
MAPT P10636 2/20 0.39
RECQL P46063 2/20 0.39
NR4A1 P22736 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11487326 0.83 SMN1; SMN2 (0.40) BRD4MEN1KMT2AHTTALDH1A1
SCHEMBL13548369 0.83 LMNA (0.55) BRD4HTTALDH1A1LMNATSHR
SCHEMBL11478019 0.79 LMNA (0.48) BRD4HTTALDH1A1LMNASCN9A
SCHEMBL11724082 0.78 LMNA (0.39) BRD4HTTALDH1A1LMNAMAPT
SCHEMBL13548366 0.74 GSK3B (0.43) KMT2AHTTALDH1A1KDM4EGAA
SCHEMBL11867921 0.74 ALDH1A1 (0.37) BRD4MEN1KMT2AHTTALDH1A1
SCHEMBL11872481 0.72 MAPT (0.45) MEN1KMT2AHTTALDH1A1KDM4E
SCHEMBL11435116 0.72 LMNA (0.35) BRD4MEN1KMT2AHTTALDH1A1
SCHEMBL11435858 0.72 FGFR1 (0.35) BRD4MEN1KMT2AHTTALDH1A1
SCHEMBL3522860 0.71 GSK3B (0.44) MEN1KMT2AHTTALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7652006-B2 For therapy and prophylaxis of neuronal loss associated with stroke, global and focal ischemia, CNS trauma, hypoglycemia and surgery, for ameliorating neurodegenerative diseases EURO-CELTIQUE S.A. (LU) 2010-01-26 US disclosed
US-20040162299-A1 Substituted quinazolines and analogs and the use thereof EURO-CELTIQUE, S.A. 2004-08-19 US disclosed
US-6765006-B2 ANTAGONISTS OF AMINO-3-HYDROXY-5-METHYLISOXAZOLE-4-PROPIONIC ACID (AMPA) IONOTROPIC RECEPTORS; NEURODEGENERATIVE, ALZHEIMER'S, AND HUNTINGTON'S DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; SCHIZOPHRENIA, EXCITATORY AMINO ACID DEFICIENCY EURO-CELTIQUE S.A. (LU) 2004-07-20 US disclosed
EP-1066039-A4 SUBSTITUTED QUINAZOLINES AND ANALOGS AND THE USE THEREOF COCENSYS INC (US) 2003-02-26 EP disclosed
US-20030033089-A1 Substituted quinazolines and analogs and the use thereof EURO-CELTIQUE S.A. 2003-02-13 US disclosed
US-6465472-B1 SUCH AS 1-(2-DIETHYLAMINOETHYL)-6,7-METHYLENEDIOXY-4-(3,4-METHYLENE -DIOXYPHENYL)QUINAZOLIN-2(1H)-ONE; AMPA IONOTROPIC RECEPTOR ANTAGONISTS; ANTICONVULSANTS, COGNITIVE ENHANCERS, PREVENTION OF NEURODEGENERATION EURO-CELTIQUE S.A. (LU) 2002-10-15 US disclosed
EP-1066039-A1 SUBSTITUTED QUINAZOLINES AND ANALOGS AND THE USE THEREOF Cocensys, Inc. (US) 2001-01-10 EP disclosed
WO-1999044612-A1 SUBSTITUTED QUINAZOLINES AND ANALOGS AND THE USE THEREOF COCENSYS, INC. (US) 1999-09-10 WO disclosed
US-3997564-A ANTIINFLAMMATORY SANDOZ, INC. (US) 1976-12-14 US disclosed
US-3978086-A INTERMEDIATES FOR 2-AMINO-4,5-METHYLENEDIOXYBENZOPHENONIMINES SANDOZ, INC. (US) 1976-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162299-A1 Substituted quinazolines and analogs and the use thereof CHRNA7, CHRNA2, CHRNA10 BRD4 2086/4885MEN1 2745/4885KMT2A 1922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.